Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon has said that the FDA has accepted the company's supplemental new drug application for Fentora for the management of breakthrough pain in opioid-tolerant patients with chronic pain.
Subscribe to our email newsletter
In addition, the FDA notified the company that it will convene an advisory committee panel on May 6, 2008, to consider this application.
Included in the Fentora (fentanyl buccal tablet) [C-II] supplemental new drug application (sNDA) are data from three randomized, placebo- controlled clinical trials and one long-term open-label safety study. The sNDA provides an evaluation of the onset of pain relief from ten minutes to two hours, and has information regarding bioequivalence data for two routes of administration.